Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma

Multiple Myeloma (MM)

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

Lancet Haematol

Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J

doi: 10.1016/S2352-3026(25)00143-7

Multiple Myeloma (MM)

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial

Lancet Haematol

Bringhen S, Cani L, Antonioli E, Derudas D, Fazio F, Larocca A, Ronconi S, Cellini C, Falcone AP, Accardi F, Liberati AM, Galieni P, Belotti A, Cafro AM, Ria R, Benevolo G, Vincelli ID, Mannina D, Lotti F, Bruno B, Marasco V, Mazza R, Tosi P, Rivolti E, Boccadoro M, D'Agostino M

doi: 10.1016/S2352-3026(25)00162-0

Multiple Myeloma (MM)

Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

Lancet Oncol

Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, Pica GM, Touzeau C, Godmer P, Slama B, Karlin L, Orsini Piocelle F, Dib M, Sanhes L, Morel P, El Yamani A, Tiab M, Tabrizi R, Richez V, Garderet L, Royer B, Bareau B, Mariette C, Fleck E, Robu D, Calmettes C, Rigaudeau S, Demarquette H, Frenzel L, Decaux O, Mohty M, Arnulf B, Bigot N, Perrot A, Corre J, Mary JY, Avet-Loiseau H, Moreau P, Leleu X, Facon T

doi: 10.1016/S1470-2045(25)00280-3

Multiple Myeloma (MM)

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

Br J Haematol

Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Ahmed S, Deeba RE, Tang G, Aljawai Y, Lee HC, Patel KK, Gaballa MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O

doi: 10.1111/bjh.70642

Multiple Myeloma (MM)

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Blood Cancer J

Foster L, Anderson LD Jr, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Badros A

doi: 10.1038/s41408-025-01355-0

Multiple Myeloma (MM)

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)

Am J Hematol

Ludwig H, Terpos E, Gay F, van de Donk NWCJ, Bernhard S, Engelhardt M, Cook G, Schjesvold F, Einsele H, Jackson G, Pawlyn C, Mateos MV, Zweegman S, Schreder M, Beksaç M, Driessen C, Ocio EM, Popat R, Rasche L, Touzeau C, Musto P, Broijl A, Dimopoulos M, Hajek R, Boccadoro M, Sonneveld P

doi: 10.1002/ajh.70397

Amyloidosis

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis

Blood

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Mollee P, Lu J, Schönland SO, Gatt ME, Suzuki K, Kim K, Cibeira MT, Bhutani M, Beksac M, Libby EN, Valent J, Hungria V, Rosenzweig MA, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman A, Goodman S, Zonder JA, Lam S, Song KW, Hansen T, Manier S, Roeloffzen WWH, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoé EQ, Tran N, Wang J, Chen Y, Vasey SY, Schecter JM, Vermeulen J, Comenzo R, Merlini G

doi: 10.1182/blood.2025032099

Multiple Myeloma (MM)

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Blood

Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWCJ, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted AJ, Vieyra D, Attar RM, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, Spencer A, Broijl A, Cupedo T, Moreau P, Boccadoro M, Sonneveld P

doi: 10.1182/blood.2025030113

Multiple Myeloma (MM)

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

Blood Cancer J

Dimopoulos MA, Lonial S, Chng WJ, Iida S, Mateos MV, Morgan GJ, Li C, Byrne C, Suryanarayan K, Labotka R, Rajkumar SV

doi: 10.1038/s41408-025-01411-9

Related content

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial

Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma